Synaffix BV
Mick Verhagen is a research associate at Synaffix BV since April 2021. Prior to this, Mick worked as a student assistant at Technische Universiteit Eindhoven and held the position of Secretaris & collaborations captain at iGEM Eindhoven. Mick also worked as a car driver at Easy Way b.v. Mick holds a Master's degree in Biomedical engineering from Eindhoven University of Technology and a Bachelor's degree in Medische wetenschappen & technologie from the same university.
This person is not in any teams
Synaffix BV
Synaffix BV is a biotech company that has established a proprietary, clinical-stage antibody-drug conjugate (ADC) technology platform that delivers best-in-class ADCs (safety and efficacy). Our platform is commercially validated by well over $7.6 billion in technology out-licensing deals with partners including ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio and Kyowa Kirin. These partnerships have rapidly translated Synaffix technology into >20 ADCs currently in development by our partners, where 5 of these have already initiated Phase 1 clinical trials. Through the platform, we can rapidly generate best-in-class ADCs for our partners from any antibody and our patent portfolio protects our proprietary processes and any resulting Products through at least 2039. Additionally, Synaffix technology is being deployed to address unmet medical need in several multi-billion-dollar, high growth market segments such as immune cell engagers and targeted gene therapy. Synaffix BV was acquired by Lonza in May 2023.